Molecular Imaging of Aortic Valve Stenosis with Positron Emission Tomography

Reindert F. Oostveen; Yannick Kaiser; Erik S. G. Stroes; Hein J. Verberne

doi:https://doi.org/10.3390/ph15070812

Molecular Imaging of Aortic Valve Stenosis with Positron Emission Tomography

Reindert F. Oostveen, Yannick Kaiser, Erik S. G. Stroes, Hein J. Verberne

Research output: Contribution to journal › Review article › Academic › peer-review

2 Citations (Scopus)

Abstract

Aortic valve stenosis (AVS) is an increasingly prevalent disease in our aging population. Although multiple risk factors for AVS have been elucidated, medical therapies capable of slowing down disease progression remain unavailable. Molecular imaging technologies are opening up avenues for the non-invasive assessment of disease progression, allowing the assessment of (early) medical interventions. This review will focus on the role of positron emission tomography of the aortic valve with18F-fluorodeoxyglucose and18F-sodium fluoride but will also shed light on novel tracers which have potential in AVS, ranging from the healthy aortic valve to end-stage valvular disease.

Original language	English
Article number	812
Journal	Pharmaceuticals
Volume	15
Issue number	7
DOIs	https://doi.org/10.3390/ph15070812
Publication status	Published - 1 Jul 2022

Keywords

aortic valve stenosis
fluorodeoxyglucose
positron emission tomography
sodium fluoride

Access to Document

https://doi.org/10.3390/ph15070812

Cite this

@article{88da03845acc4bed8b0f36ecc3ae8347,

title = "Molecular Imaging of Aortic Valve Stenosis with Positron Emission Tomography",

abstract = "Aortic valve stenosis (AVS) is an increasingly prevalent disease in our aging population. Although multiple risk factors for AVS have been elucidated, medical therapies capable of slowing down disease progression remain unavailable. Molecular imaging technologies are opening up avenues for the non-invasive assessment of disease progression, allowing the assessment of (early) medical interventions. This review will focus on the role of positron emission tomography of the aortic valve with18F-fluorodeoxyglucose and18F-sodium fluoride but will also shed light on novel tracers which have potential in AVS, ranging from the healthy aortic valve to end-stage valvular disease.",

keywords = "aortic valve stenosis, fluorodeoxyglucose, positron emission tomography, sodium fluoride",

author = "Oostveen, {Reindert F.} and Yannick Kaiser and Stroes, {Erik S. G.} and Verberne, {Hein J.}",

note = "Funding Information: Funding: Y.K. and E.S.G.S. were supported by the Netherlands Heart Foundation CVON 2017-20: generating the best evidence-based pharmaceutical targets for atherosclerosis (GENIUS II). Publisher Copyright: {\textcopyright} 2022 by the authors. Licensee MDPI, Basel, Switzerland.",

year = "2022",

month = jul,

day = "1",

doi = "https://doi.org/10.3390/ph15070812",

language = "English",

volume = "15",

journal = "Pharmaceuticals",

issn = "1424-8247",

publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",

number = "7",

}

TY - JOUR

T1 - Molecular Imaging of Aortic Valve Stenosis with Positron Emission Tomography

AU - Oostveen, Reindert F.

AU - Kaiser, Yannick

AU - Stroes, Erik S. G.

AU - Verberne, Hein J.

N1 - Funding Information: Funding: Y.K. and E.S.G.S. were supported by the Netherlands Heart Foundation CVON 2017-20: generating the best evidence-based pharmaceutical targets for atherosclerosis (GENIUS II). Publisher Copyright: © 2022 by the authors. Licensee MDPI, Basel, Switzerland.

PY - 2022/7/1

Y1 - 2022/7/1

N2 - Aortic valve stenosis (AVS) is an increasingly prevalent disease in our aging population. Although multiple risk factors for AVS have been elucidated, medical therapies capable of slowing down disease progression remain unavailable. Molecular imaging technologies are opening up avenues for the non-invasive assessment of disease progression, allowing the assessment of (early) medical interventions. This review will focus on the role of positron emission tomography of the aortic valve with18F-fluorodeoxyglucose and18F-sodium fluoride but will also shed light on novel tracers which have potential in AVS, ranging from the healthy aortic valve to end-stage valvular disease.

AB - Aortic valve stenosis (AVS) is an increasingly prevalent disease in our aging population. Although multiple risk factors for AVS have been elucidated, medical therapies capable of slowing down disease progression remain unavailable. Molecular imaging technologies are opening up avenues for the non-invasive assessment of disease progression, allowing the assessment of (early) medical interventions. This review will focus on the role of positron emission tomography of the aortic valve with18F-fluorodeoxyglucose and18F-sodium fluoride but will also shed light on novel tracers which have potential in AVS, ranging from the healthy aortic valve to end-stage valvular disease.

KW - aortic valve stenosis

KW - fluorodeoxyglucose

KW - positron emission tomography

KW - sodium fluoride

UR - http://www.scopus.com/inward/record.url?scp=85133540489&partnerID=8YFLogxK

U2 - https://doi.org/10.3390/ph15070812

DO - https://doi.org/10.3390/ph15070812

M3 - Review article

C2 - 35890111

SN - 1424-8247

VL - 15

JO - Pharmaceuticals

JF - Pharmaceuticals

IS - 7

M1 - 812

ER -

Molecular Imaging of Aortic Valve Stenosis with Positron Emission Tomography

Abstract

Keywords

Access to Document

Other files and links

Cite this